Wegovy vs. Farxiga
See how Wegovy and Farxiga compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Wegovy is a once-weekly injectable GLP-1 for weight loss and cardiovascular risk reduction, while Farxiga is a once-daily oral SGLT2 inhibitor for diabetes, heart failure, and kidney disease.
Wegovy's most common side effects are gastrointestinal, while Farxiga's are mostly genital and urinary infections.
Both drugs have cardiovascular benefits, but Wegovy targets heart risk tied to obesity while Farxiga targets heart failure and kidney decline in diabetes.
Wegovy vs. Farxiga Drug Summary
Wegovy
Wegovy is a GLP-1 receptor agonist given as a once-weekly injection. It is approved for chronic weight management in adults and adolescents with obesity or overweight plus a related health condition, and to lower cardiovascular risk in adults with heart disease and excess weight. Dosing starts low and increases every four weeks up to a 2.4 mg maintenance dose.
Farxiga
Farxiga is an SGLT2 inhibitor taken as a once-daily tablet. It is approved for blood sugar control in type 2 diabetes, plus reducing hospitalization and death from heart failure and slowing chronic kidney disease progression. Most patients start at 5 mg and may increase to 10 mg daily depending on the condition treated.
Wegovy vs. Farxiga Side Effects
Wegovy
Farxiga
Wegovy vs. Farxiga Dosage
Wegovy
Farxiga
| STAGE | DOSE | WHEN |
| Starting dose | 0.25 mg once weekly | Weeks 1-4 |
| Maximum dose | 2.4 mg once weekly | Week 17 onward |
| Dose changes | 4 increases | Every 4 weeks |
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg once daily | At the start |
| Maximum dose | 10 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Wegovy
| STAGE | DOSE | WHEN |
| Starting dose | 0.25 mg once weekly | Weeks 1-4 |
| Maximum dose | 2.4 mg once weekly | Week 17 onward |
| Dose changes | 4 increases | Every 4 weeks |
Farxiga
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg once daily | At the start |
| Maximum dose | 10 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Wegovy vs. Farxiga Indications
Wegovy
Wegovy is FDA-approved for long-term weight management in adults and adolescents 12 and older who have obesity or are overweight with a related condition like high blood pressure or type 2 diabetes. It also carries approval for reducing major cardiovascular events in adults with established heart disease who are overweight or obese. It is not approved for treating diabetes itself.
Chronic weight management with obesity or overweight plus a weight-related condition
Approved for adolescents 12 and older
Reduces risk of heart attack, stroke, and cardiovascular death in adults with heart disease
Used alongside diet and exercise
Farxiga
Farxiga is FDA-approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes. It is also approved to reduce heart failure hospitalization and cardiovascular death, and to slow the progression of chronic kidney disease, regardless of diabetes status. It is not approved for weight loss.
Blood sugar control in type 2 diabetes, ages 10 and up
Reduces hospitalization and death from heart failure (reduced or preserved ejection fraction)
Slows kidney function decline in chronic kidney disease
Used with diet and exercise as part of diabetes care
Wegovy vs. Farxiga Pros and Cons
Wegovy
Wegovy delivers substantial weight loss and is the only anti-obesity medication with FDA approval to reduce cardiovascular events in overweight or obese adults with heart disease. It requires a weekly injection and a gradual dose increase over several months, and insurance coverage for weight loss indications can be inconsistent.
Pros
FDA-approved specifically to reduce cardiovascular events in overweight or obese adults with heart disease
Produces substantial weight loss, more than most other anti-obesity medications
Only needs to be injected once a week
Cons
Common gastrointestinal side effects like nausea and vomiting during dose increases
Boxed warning for thyroid C-cell tumor risk seen in animal studies
Requires an injection rather than a pill
Roughly $1,300 to $1,350 per month without insurance, before savings programs
Farxiga
Farxiga is a once-daily pill with years of real-world use and FDA approval across diabetes, heart failure, and chronic kidney disease. It produces only modest weight loss compared to Wegovy, and it carries its own risks like genital infections and volume depletion.
Pros
Taken as a once-daily oral tablet, no injections needed
Approved for four distinct conditions: diabetes, two types of heart failure, and chronic kidney disease
Long safety track record since FDA approval in 2014
Cons
Not intended for significant weight loss, effects are modest compared to Wegovy
Risk of genital yeast infections and urinary tract infections
Rare but serious risk of ketoacidosis and Fournier's gangrene
Not recommended for glycemic control in advanced kidney disease
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.